Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Paying user area
Try for free
Cigna Group pages available for free this week:
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Cigna Group for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Profitability Ratios (Summary)
Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
The financial data reveals several notable trends in the profitability and efficiency metrics over the observed periods from March 2020 through December 2024.
- Gross Profit Margin
-
The gross profit margin, starting from the first available quarter in March 2021 at 14.43%, exhibits a consistent declining trend across the subsequent periods. From above 14%, it gradually declines to 12.19% by September 2023 and continues to decrease further, reaching approximately 10.15% by the final reported quarter, December 2024. This persistent downward trend suggests increasing cost pressures or a deterioration in pricing power over time.
- Operating Profit Margin
-
This margin follows a pattern similar to the gross profit margin. Beginning at 5.12% in March 2021, it slightly fluctuates but generally decreases quarter over quarter, ending at 3.83% by the end of 2024. Despite minor upticks observed during some quarters in 2022 and 2023, the overall decline indicates that operating costs might be growing at a faster pace than revenues, reducing operational efficiency.
- Net Profit Margin
-
The net profit margin shows a sharper decline relative to gross and operating margins. It drops from 5.31% in the first quarter of 2021 to a low of 1.31% by September 2024 before a slight recovery to 1.4% in the last quarter of 2024. The steep decrease could be attributable to higher interest expenses, increased taxes, or extraordinary items impacting net results. The slight recovery toward the end of the period might indicate initial signs of stabilization.
- Return on Equity (ROE)
-
Initially strong at values near 17% in early 2021, ROE experiences a downward trajectory, falling below 12% by mid-2022. It recovers somewhat to near 15% during 2022 and early 2023 but then declines again steadily from late 2023 onwards, reaching lows around 7%–8% by the end of 2024. This volatility in ROE mirrors the diminished profitability and suggests challenges in generating returns for shareholders at prior levels.
- Return on Assets (ROA)
-
ROA moves similarly to ROE, starting at approximately 5.44% in early 2021, declining to about 3.46% by early 2022, then rising modestly to near 4.63% in late 2022. Afterward, the trend reverses again, dropping steadily to about 2.2% by the end of 2024. This pattern implies a decline in asset utilization efficiency over time, paralleling the reduction in overall profitability.
Overall, the data signals deteriorating profitability margins and returns, with the most pronounced decreases occurring in net margin and ownership returns (ROE and ROA). The consistent decline across multiple key metrics suggests that the company could be facing increasing costs, pricing pressures, or operational inefficiencies that are impacting both its earnings capacity and asset utilization. Although some temporary recoveries are noted around late 2022 to early 2023, the general trend remains downward through to the end of 2024.
Return on Sales
Return on Investment
Gross Profit Margin
Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
Gross profit | ||||||||||||||||||||||||||
Revenues from external customers | ||||||||||||||||||||||||||
Profitability Ratio | ||||||||||||||||||||||||||
Gross profit margin1 | ||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||
Gross Profit Margin, Competitors2 | ||||||||||||||||||||||||||
Abbott Laboratories | ||||||||||||||||||||||||||
CVS Health Corp. | ||||||||||||||||||||||||||
Elevance Health Inc. | ||||||||||||||||||||||||||
Intuitive Surgical Inc. | ||||||||||||||||||||||||||
Medtronic PLC | ||||||||||||||||||||||||||
UnitedHealth Group Inc. |
Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q4 2024 Calculation
Gross profit margin = 100
× (Gross profitQ4 2024
+ Gross profitQ3 2024
+ Gross profitQ2 2024
+ Gross profitQ1 2024)
÷ (Revenues from external customersQ4 2024
+ Revenues from external customersQ3 2024
+ Revenues from external customersQ2 2024
+ Revenues from external customersQ1 2024)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The financial data over the reported quarters reveal several noteworthy trends in the company's performance metrics related to gross profit, revenues from external customers, and gross profit margin.
- Gross Profit
- Gross profit demonstrates moderate fluctuation over the observed period. Initially, it peaks around the second quarter of 2020, reaching approximately 6,319 million USD, followed by a decline toward the end of 2020. Subsequently, gross profit experiences a gradual upward trajectory starting in the first quarter of 2023, where it crosses 6,000 million USD, reaching a peak of around 6,517 million USD during the third quarter of 2024 before slightly declining in the last reported quarter. This suggests some growth in profitability during recent quarters after a period of relative stagnation through 2021 and 2022.
- Revenues from External Customers
- Revenue figures indicate a consistent upward trend throughout the entire period. Beginning at approximately 38,116 million USD in the first quarter of 2020, revenues steadily increase quarter over quarter, surpassing 65,000 million USD by the last reported quarter in 2024. The growth pace appears particularly accelerated starting in early 2023, possibly reflecting expanded business activities or market share gains driving higher top-line performance.
- Gross Profit Margin
- The gross profit margin exhibits a clear declining trend over time. From a margin around 14.43% in early 2020, the ratio diminishes progressively, reaching approximately 10.15% by the end of 2024. This decline suggests that despite increasing revenues, the company is experiencing rising costs or pricing pressures that erode profitability on a relative basis. Decreasing gross profit margins alongside growing revenues may indicate competitive challenges or shifts in cost structures affecting the initial profit efficiency.
In summary, the company has achieved consistent revenue growth over the analyzed timeframe with gross profits modestly increasing after an initial volatile period. However, the continuous decrease in gross profit margin signals potential margin compression, which warrants further investigation into cost management or pricing strategies to enhance profit sustainability.
Operating Profit Margin
Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
Income from operations | ||||||||||||||||||||||||||
Revenues from external customers | ||||||||||||||||||||||||||
Profitability Ratio | ||||||||||||||||||||||||||
Operating profit margin1 | ||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||
Operating Profit Margin, Competitors2 | ||||||||||||||||||||||||||
Abbott Laboratories | ||||||||||||||||||||||||||
CVS Health Corp. | ||||||||||||||||||||||||||
Elevance Health Inc. | ||||||||||||||||||||||||||
Intuitive Surgical Inc. | ||||||||||||||||||||||||||
Medtronic PLC | ||||||||||||||||||||||||||
UnitedHealth Group Inc. |
Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q4 2024 Calculation
Operating profit margin = 100
× (Income from operationsQ4 2024
+ Income from operationsQ3 2024
+ Income from operationsQ2 2024
+ Income from operationsQ1 2024)
÷ (Revenues from external customersQ4 2024
+ Revenues from external customersQ3 2024
+ Revenues from external customersQ2 2024
+ Revenues from external customersQ1 2024)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
- Income from Operations
- The income from operations fluctuates throughout the periods with noticeable quarterly variations. Starting at 2,061 million USD in March 2020, there is a rise to 2,639 million USD by June 2020, followed by a decline to 1,345 million USD by December 2020. A similar pattern of increases and decreases occurs in subsequent years. Notably, the income peaks at 2,576 million USD in September 2024, followed by a decrease to 2,173 million USD by December 2024. Overall, while there are positive spikes, the income does not demonstrate a consistent upward trend and shows some volatility quarter to quarter.
- Revenues from External Customers
- Revenues from external customers exhibit an overall upward trend over the analyzed timeframe. Beginning at 38,116 million USD in March 2020, the revenues steadily increase each quarter, reaching 65,372 million USD by March 2024. There are minor fluctuations, but the general trajectory indicates growth in revenue generation, with several periods of accelerated increments, particularly between 2023 and 2024. This suggests an expansion in sales or customer base over the four-year period.
- Operating Profit Margin
- The operating profit margin data is available from September 2020 onwards and shows a gradual decline over time. Initially recorded at 5.12% in September 2020, the margin reduces steadily to 3.83% by December 2024. This steady decrease implies that despite rising revenues, the proportion of profit derived from operating activities relative to revenue is diminishing. This could indicate increasing operating costs or reduced operational efficiency over these periods.
- Summary
- The financial data reveals a scenario where revenues are increasing steadily, reflecting growth in business activities. However, income from operations shows volatility and lacks a clear upward trend, suggesting challenges in maintaining consistent operational profitability. Furthermore, the declining operating profit margin points to shrinking profitability relative to revenue, highlighting potential issues in cost control or pricing strategy. The combination of these trends suggests that while revenue growth is positive, improving operational efficiency and profit margins may require focused managerial attention.
Net Profit Margin
Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
Shareholders’ net income (loss) | ||||||||||||||||||||||||||
Revenues from external customers | ||||||||||||||||||||||||||
Profitability Ratio | ||||||||||||||||||||||||||
Net profit margin1 | ||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||
Net Profit Margin, Competitors2 | ||||||||||||||||||||||||||
Abbott Laboratories | ||||||||||||||||||||||||||
CVS Health Corp. | ||||||||||||||||||||||||||
Elevance Health Inc. | ||||||||||||||||||||||||||
Intuitive Surgical Inc. | ||||||||||||||||||||||||||
Medtronic PLC | ||||||||||||||||||||||||||
UnitedHealth Group Inc. |
Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q4 2024 Calculation
Net profit margin = 100
× (Shareholders’ net income (loss)Q4 2024
+ Shareholders’ net income (loss)Q3 2024
+ Shareholders’ net income (loss)Q2 2024
+ Shareholders’ net income (loss)Q1 2024)
÷ (Revenues from external customersQ4 2024
+ Revenues from external customersQ3 2024
+ Revenues from external customersQ2 2024
+ Revenues from external customersQ1 2024)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The quarterly financial data reveals several notable trends and patterns over the observed periods.
- Shareholders’ net income (loss)
- Net income demonstrated significant volatility throughout the period. Initially, the value increased sharply from 1,181 million US$ in March 2020 to a peak of 4,135 million US$ in December 2020. However, this gain was not sustained; following December 2020, net income declined notably, with fluctuations observed in the subsequent quarters. Particularly, the net income decreased to a negative 277 million US$ in June 2024, marking a substantial downturn. Despite this, some recovery occurred later in 2024, though figures remained below prior high levels. The overall pattern suggests periods of strong profitability interrupted by volatility and some negative performance.
- Revenues from external customers
- Revenues exhibited a consistent upward trend across the entire span. Beginning at approximately 38,116 million US$ in March 2020, revenues grew steadily each quarter. By December 2024, total revenues had increased to around 65,372 million US$, indicating sustained growth in customer income. The steady increase in revenues contrasts with the volatility observed in net income, suggesting that while sales or service volumes grew, profitability faced challenges possibly due to rising costs or other factors impacting margins.
- Net profit margin
- Profit margin data are available from December 2020 onward and depict a declining trend. Starting at 5.31% in December 2020, the margin fell gradually over time, reaching lows near 1.31% by September 2024 before a slight recovery to 1.4% at year-end. This downward trend in profit margin indicates decreasing efficiency in converting revenue into profit, which aligns with the observed fluctuations in net income despite increasing revenues. The decline suggests rising expenses, pricing pressures, or other operational challenges affecting profitability.
Overall, the financial data indicate robust revenue growth but weakening profitability, highlighted by declining net profit margins and volatile net income figures. This pattern suggests that while demand or sales volumes increased, the company faced challenges in managing costs or sustaining profit levels over the reported periods.
Return on Equity (ROE)
Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
Shareholders’ net income (loss) | ||||||||||||||||||||||||||
Shareholders’ equity | ||||||||||||||||||||||||||
Profitability Ratio | ||||||||||||||||||||||||||
ROE1 | ||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||
ROE, Competitors2 | ||||||||||||||||||||||||||
Abbott Laboratories | ||||||||||||||||||||||||||
CVS Health Corp. | ||||||||||||||||||||||||||
Elevance Health Inc. | ||||||||||||||||||||||||||
Intuitive Surgical Inc. | ||||||||||||||||||||||||||
Medtronic PLC | ||||||||||||||||||||||||||
UnitedHealth Group Inc. |
Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q4 2024 Calculation
ROE = 100
× (Shareholders’ net income (loss)Q4 2024
+ Shareholders’ net income (loss)Q3 2024
+ Shareholders’ net income (loss)Q2 2024
+ Shareholders’ net income (loss)Q1 2024)
÷ Shareholders’ equity
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
- Shareholders’ Net Income (Loss)
- The net income exhibited noticeable fluctuations over the reported quarters. Initially, between March 2020 and December 2020, net income showed an overall increasing trend, peaking significantly in December 2020 at 4,135 million USD. Following this peak, net income declined substantially in the first quarter of 2021, then presented moderate fluctuations through 2021 and 2022, with values generally ranging between 1,100 and 2,750 million USD. In 2023, the net income remained relatively stable in the range of approximately 1,200 to 1,460 million USD until the last quarter, where it slightly decreased. Entering 2024, net income demonstrated more volatility, including a notable negative figure (-277 million USD) in June 2024, followed by recovery to positive income values in subsequent quarters. The data suggests intermittent earnings volatility with a significant peak in late 2020 and some instability in early 2024.
- Shareholders’ Equity
- Shareholders' equity started at 45,079 million USD in March 2020, with a general upward trend reaching a high of 50,321 million USD by December 2020. From 2021 onwards, equity showed a gradual decline with some quarter-to-quarter variability, ultimately decreasing to around 44,502 million USD by March 2023. The equity levels slightly recovered through 2023 and early 2024 but displayed a downward shift again in mid-2024, ending near 41,033 million USD by December 2024. Overall, the equity experienced an initial increase followed by a steady decline, indicating potential distribution to shareholders, asset write-downs, or accumulated losses over the medium term.
- Return on Equity (ROE)
- Return on equity was first reported in December 2020 at 16.81%, remaining relatively stable and strong through 2021 with values between 16.73% and 17.68%. Entering 2022, a notable decline in ROE occurred, decreasing to the 11-15% range, and this moderate level persisted through 2023. In 2024, ROE declined further, falling below 9% and reaching as low as 7.22% in September 2024 before a slight improvement in the final quarter. This downward trend in ROE over time suggests diminishing profitability relative to shareholder equity, reflecting the decline in net income and the contraction of equity during the latter periods.
Return on Assets (ROA)
Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Selected Financial Data (US$ in millions) | ||||||||||||||||||||||||||
Shareholders’ net income (loss) | ||||||||||||||||||||||||||
Total assets | ||||||||||||||||||||||||||
Profitability Ratio | ||||||||||||||||||||||||||
ROA1 | ||||||||||||||||||||||||||
Benchmarks | ||||||||||||||||||||||||||
ROA, Competitors2 | ||||||||||||||||||||||||||
Abbott Laboratories | ||||||||||||||||||||||||||
CVS Health Corp. | ||||||||||||||||||||||||||
Elevance Health Inc. | ||||||||||||||||||||||||||
Intuitive Surgical Inc. | ||||||||||||||||||||||||||
Medtronic PLC | ||||||||||||||||||||||||||
UnitedHealth Group Inc. |
Based on: 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31).
1 Q4 2024 Calculation
ROA = 100
× (Shareholders’ net income (loss)Q4 2024
+ Shareholders’ net income (loss)Q3 2024
+ Shareholders’ net income (loss)Q2 2024
+ Shareholders’ net income (loss)Q1 2024)
÷ Total assets
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
- Shareholders’ net income (loss)
- The shareholders' net income demonstrated considerable volatility over the observed periods. From March 2020 to December 2020, net income showed a fluctuating upward trend, peaking at 4,135 million USD by the end of the year. In 2021, income figures stabilized somewhat, maintaining values mostly between 1,100 and 1,600 million USD, with a notable increase to 2,757 million USD in September 2022. However, from early 2023 onward, the results indicated irregular performance, including a significant loss of 277 million USD in June 2024, contrasting with subsequent recoveries.
- Total assets
- Total assets remained relatively stable throughout the entire timeframe. Beginning at approximately 155 billion USD in March 2020, the asset base showed minor fluctuations but generally maintained a range between 143 billion and 157 billion USD. The highest asset value was recorded in September 2024 at around 157.6 billion USD, followed by a slight decrease at year-end 2024.
- Return on Assets (ROA)
- The ROA showed an initial upward direction, reaching about 5.5% by the end of 2020. However, starting in 2021, ROA began a gradual decline, dropping from around 5.3% to approximately 4.4% into late 2022. The trend continued downward throughout 2023 and 2024, reaching as low as about 1.9% by September 2024, with a minimal recovery thereafter. This declining ROA indicates diminishing efficiency in asset utilization over the later periods.